<!DOCTYPE html>
<html lang="en">
<head><!-- Google Tag Manager --> <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-N4XZHNC');</script> <!-- End Google Tag Manager -->

<title>Vibegron: Mechanism, Adverse Effects and Contraindications</title>
  <meta charset="utf-8">
  
  <link href="urology2.css" rel="stylesheet">

<meta name="keywords" content="Vibegron, beta3 receptor agonist, neurogenic lower urinary tract dysfunction, overactive bladder" >
<meta name="description" content="Pharmacological profile of Vibegron for the treatment of neurogenic lower urinary tract dysfunction and overactive bladder..., from the online textbook of urology by D. Manski" >
<meta name="author" content="Dr. med. Dirk Manski" >
<meta name="copyright" content="Dirk Manski" >
<meta name="robots" content="index">
<meta name="robots" content="follow">
<meta name="viewport" content="width=device-width, initial-scale=1">
 </head>

<body><!-- Google Tag Manager (noscript) --> <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-N4XZHNC" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript> <!-- End Google Tag Manager (noscript) --> 
<header>
    <a class="ribbon" tabindex="-1" title="back to start!" href="https://www.urology-textbook.com/index.html">
	   <p><span style="font-size: 1.2em;">Urology Textbook</span><br>
       
       <span style="font-size: 0.8em;">Clinical Essentials</span>
       <br>
       <span style="font-size: 0.6em;">By Dirk Manski, MD</span></p>
    </a>  
</header>
<main> 
<article>
<nav role="navigation">
<div id="menuToggle">
<input type="checkbox" id="menuCheckbox" />
     <span></span>
    <span></span>
    <span></span>
<ul id="menu">
<li>
        <a href="https://www.urology-textbook.com/anatomy.html">
          <label for="menuCheckbox" onclick="this.parentNode.click();">Anatomy</label>
        </a>
      </li>
<li><a href="https://www.urology-textbook.com/signs-and-symptoms.html">Signs and Symptoms</a></li>
<li><a href="https://www.urology-textbook.com/examinations.html">Examinations</a></li>
<li><a href="https://www.urology-textbook.com/surgical-management.html">Surgical Management</a></li>
<li><a href="https://www.urology-textbook.com/pharmacology.html">Pharmacology</a></li>
<li><a href="https://www.urology-textbook.com/kidneys.html">Kidneys</a></li>
<li><a href="https://www.urology-textbook.com/ureters.html">Ureters</a></li>
<li><a href="https://www.urology-textbook.com/bladder.html">Bladder</a></li>
<li><a href="https://www.urology-textbook.com/prostate.html">Prostate</a></li>
<li><a href="https://www.urology-textbook.com/urethra.html">Urethra</a></li>
<li><a href="https://www.urology-textbook.com/penis.html">Penis</a></li>
<li><a href="https://www.urology-textbook.com/testes.html">Testes</a></li>
<li><a href="https://www.urology-textbook.com/adrenal-glands.html">Adrenal Glands</a></li>
<li><a href="https://www.urology-textbook.com/common-diseases.html">Common Diseases</a></li>
<li><a href="https://www.urology-textbook.com/urologic-surgery.html">Urologic Surgery</a></li>
<li><a href="https://www.urology-textbook.com/index-urology.html">Index</a></li>
<li><a href="https://www.urology-textbook.com/medical-abbreviations.html">Abbreviations</a></li>
<li><a href="https://www.urology-textbook.com/urology-news.html">News</a></li>
<li><a href="https://www.urology-textbook.com/links.html">Links</a></li>
</ul>

</div>
</nav>

<p id="brotkrumen">&nbsp;You are here: <a href="https://www.urology-textbook.com/index.html">Urology Textbook</a>  &gt; <a href="https://www.urology-textbook.com/pharmacology.html">Drugs in Urology</a> &gt; Vibegron</p>

<h1>Vibegron: Mechanism of Action, Adverse Effects, Contraindications, and Dosing</h1>

<h2>Mechanism of Action of Vibegron</h2> 
<p>Vibegron is a &beta;3-adrenergic receptor agonist. In the urinary bladder, vibegron increases intracellular cAMP and relaxes detrusor smooth muscle <a href="https://www.urology-textbook.com/bladder-function.html">during the filling phase</a>, thereby increasing functional bladder capacity.</p>

<p><img src="https://images2.urology-textbook.com/vibegron.jpg" width="200" alt="Structural formula of vibegron" title="Vibegron"></p>

<h2>Urologic Indications for Vibegron:</h2> 

<p>Vibegron provides symptomatic treatment of <a href="https://www.urology-textbook.com/overactive-bladder.html">urgency symptoms associated with overactive bladder (OAB)</a> in adults. In the pivotal phase III EMPOWUR trial (randomized, double-blind, 12 weeks; vibegron 75&nbsp;mg vs placebo vs tolterodine; n=1518), vibegron improved mean daily micturition frequency, urgency urinary incontinence episodes, and increased mean voided volume compared with placebo. Adverse events led to treatment discontinuation in 1.7% of patients (compared with 3.3% with tolterodine).</p>

<h2>Pharmacokinetics of Vibegron</h2> 

<p>Oral <a href="https://www.urology-textbook.com/bioavailability.html">bioavailability</a> is approximately 57%, and patients may take vibegron with or without food. The liver metabolizes vibegron only to a limited extent, and a substantial fraction is eliminated unchanged in urine. The half-life is approximately 31&nbsp;hours, and patients generally reach steady state after seven days.</p>

<h2>Adverse Effects of Vibegron</h2> 

<p>Vibegron appears to have fewer cardiovascular adverse effects in the pivotal trials compared to mirabegron.</p>

<ul>
<li>Common (&lt;10%): <a href="https://www.urology-textbook.com/urinary-tract-infection.html">urinary tract infections</a>, headache, constipation, diarrhea, nausea, and an increase in postvoid residual urine volume.</li>
<li>Uncommon (&lt;1%): hot flashes, rash, and <a href="https://www.urology-textbook.com/urinary-retention.html">urinary retention</a>.</li>
</ul>

<h3>Drug Interactions:</h3> 

<p>Vibegron can increase exposure to P-glycoprotein (P-gp) substrates, consider increased exposure for other sensitive P-gp substrates, including digoxin, dabigatran, apixaban, or rivaroxaban.</p>

<p>Combination therapy with <a href="https://www.urology-textbook.com/anticholinergics.html">antimuscarinics</a> can improve symptom control, but it can increase the risk of urinary retention, especially in patients with clinically significant <a href="https://www.urology-textbook.com/benign-prostatic-hyperplasia.html">bladder outlet obstruction</a>.</p>


<h2>Contraindications of Vibegron</h2> 

<p>Hypersensitivity to the active ingredient. Vibegron is not recommended during pregnancy, breastfeeding, severe hepatic impairment (Child-Pugh C), and <a href="https://www.urology-textbook.com/chronic-kidney-disease.html">end-stage renal disease (GFR &lt;15&nbsp;ml/min)</a> because of limited data.</p>

<h2>Dosing of Vibegron</h2>  

<ul>
    <li>Adults: 75&nbsp;mg p.o. once daily.</li>
    <li>No dose adjustment is necessary in mild to severe renal impairment (15&nbsp;ml/min &lt; GFR &lt; 90&nbsp;ml/min) or in mild to moderate hepatic impairment (Child-Pugh A or B).</li>
</ul>

<br>
<br>

<div id="ad-footer">
<!-- ad-footer -->
<ins class="adsbygoogle"
     style="display:inline-block;width:500px;height:250px"
     data-ad-client="ca-pub-9284927104423861"
     data-ad-slot="8746163219"></ins>
 <script>
     (adsbygoogle = window.adsbygoogle || []).push({});
</script>
</div>
<br><table id="navigation_unten">
<tr>
 
<td><a href="https://www.urology-textbook.com/mirabegron.html">Mirabegron</a></td>
<td><a class="nav4" href="https://www.urology-textbook.com/index-urology.html">Index</a></td>
<td><a class="nav3" href="https://www.urology-textbook.com/bleomycin.html">Bleomycin</a></td>
 
</tr>
</table>

<br>
<br>
Index: <a href="https://www.urology-textbook.com/index-urology-a.html">1&ndash;9</a> <a href="https://www.urology-textbook.com/index-urology-a.html">A</a> <a href="https://www.urology-textbook.com/index-urology-b.html">B</a> <a href="https://www.urology-textbook.com/index-urology-c.html">C</a> <a href="https://www.urology-textbook.com/index-urology-d.html">D</a> <a href="https://www.urology-textbook.com/index-urology-e.html">E</a> <a href="https://www.urology-textbook.com/index-urology-f.html">F</a> <a href="https://www.urology-textbook.com/index-urology-g.html">G</a> <a href="https://www.urology-textbook.com/index-urology-h.html">H</a> <a href="https://www.urology-textbook.com/index-urology-i.html">I</a> <a href="https://www.urology-textbook.com/index-urology-j.html">J</a> <a href="https://www.urology-textbook.com/index-urology-k.html">K</a> <a href="https://www.urology-textbook.com/index-urology-l.html">L</a> <a href="https://www.urology-textbook.com/index-urology-m.html">M</a> <a href="https://www.urology-textbook.com/index-urology-n.html">N</a> <a href="https://www.urology-textbook.com/index-urology-o.html">O</a> <a href="https://www.urology-textbook.com/index-urology-p.html">P</a> <a href="https://www.urology-textbook.com/index-urology-q.html">Q</a> <a href="https://www.urology-textbook.com/index-urology-r.html">R</a> <a href="https://www.urology-textbook.com/index-urology-s.html">S</a> <a href="https://www.urology-textbook.com/index-urology-t.html">T</a> <a href="https://www.urology-textbook.com/index-urology-u.html">U</a> <a href="https://www.urology-textbook.com/index-urology-v.html">V</a> <a href="https://www.urology-textbook.com/index-urology-w.html">W</a> <a href="https://www.urology-textbook.com/index-urology-xyz.html">X Y Z</a> 

<br>
<br>
<h3>References</h3>

<p>D. Staskin, J. Frankel, S. Varano, D. Shortino, R. Jankowich, and P. N. Mudd, “International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR.,” J Urol, vol. 204, no. 2, pp. 316–324, 2020, doi: 10.1097/JU.0000000000000807.</p>
   
<p>J. Frankel, D. Staskin, S. Varano, M. J. Kennelly, R. A. Jankowich, and C. Haag-Molkenteller, “An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive Bladder.,” Ther Clin Risk Manag, vol. 18, pp. 171–182, 2022, doi: 10.2147/TCRM.S310371.</p>
<br>
<br>
<p><img src="https://images0.urology-textbook.com/deutsch.gif">&nbsp; Deutsche Version: <a href="https://www.urologielehrbuch.de/vibegron.html">Mechanismus, Nebenwirkungen und Kontraindikationen von Vibegron</a></p>

<h3>Urology-Textbook.com – Choose the Ad-Free, Professional Resource</h3>
<p>This website is designed for physicians and medical professionals. It presents diseases of the genital organs through detailed text and images. Some content may not be suitable for children or sensitive readers. Many illustrations are available exclusively to Steady members. Are you a physician and interested in supporting this project? <a href="https://steady.page/de/urology/about">Join Steady to unlock full access</a> to all images and enjoy an ad-free experience. Try it free for 7 days&mdash;no obligation. </p>

<p><strong>New release:</strong> The first edition of the Urology Textbook as an e-book&mdash;ideal for offline reading and quick reference. With over 1300 pages and hundreds of illustrations, it’s the perfect companion for residents and medical students. After your 7-day trial has ended, you will receive a download link for your exclusive e-book.</p>
</article>
</main>
<footer class="grid">
    <ul id="footer-nav">
    		<li>Copyright by Dr. med. Dirk Manski </li>
		<li><a href="https://www.urology-textbook.com/privacy-policy.html">Privacy policy</a></li>
		<li><a href="https://www.urology-textbook.com/disclaimer.html">Disclaimer</a></li>
	</ul>
	<a class="steady-login-button" data-size="medium" data-language="en" style="display: none;"></a>
</footer>
</body>
</html>
